Quifenadine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bgwhite (talk | contribs) at 06:52, 5 January 2016 (fix ordinals per WP:ORDINAL using AWB (11756)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Quifenadine
Clinical data
Trade namesFencarol
Other names3-quinuclidinyldiphenylmethanol
Routes of
administration
Oral (tablets), IM
ATC code
Legal status
Legal status
  • OTC (tablets), ℞-only (solution for IM injection) (RU)
Pharmacokinetic data
Bioavailability45% (Tmax = 1 hour)[1]
MetabolismHepatic
Identifiers
  • 1-azabicyclo[2.2.2]octan-3-yl(diphenyl)methanol
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23NO
Molar mass293.40 g/mol g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)(c2ccccc2)C4C3CCN(CC3)C4
  • InChI=1S/C20H23NO/c22-20(17-7-3-1-4-8-17,18-9-5-2-6-10-18)19-15-21-13-11-16(19)12-14-21/h1-10,16,19,22H,11-15H2
  • Key:PZMAHNDJABQWGS-UHFFFAOYSA-N

Quifenadine (Russian: хифенадин, trade name: Phencarol, Фенкарол) is an 2nd generation antihistamine drug, marketed mainly in post-Soviet countries.[2][3] Chemically, it is a quinuclidine derivative.

Indications

References

  1. ^ a b "Fencarol (quifenadine) Tablets, for Oral Use. Full Prescribing Information". State Register of Medicines (in Russian). Retrieved 4 January 2016.
  2. ^ "Quifenadine". Drugs.com. Retrieved 28 January 2014.
  3. ^ Makarov, L.; Balykova, L.; Soldatova, O.; Komolyatova, V.; Serebruany, V. (2010). "The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: A randomized controlled pilot trial". American journal of therapeutics. 17 (4): 396–401. doi:10.1097/MJT.0b013e3181a86987. PMID 19487925.